Oral Cancer Detection Increased with Saliva Test
|
By LabMedica International staff writers Posted on 10 May 2012 |
A simple saliva test has been created which could identify the presence of biomarkers that are associated with oral cancer.
The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.
A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.
Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."
Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.
Related Links:
Michigan State University
University of California
Delta Dental
The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.
A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.
Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."
Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.
Related Links:
Michigan State University
University of California
Delta Dental
Latest Pathology News
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
- AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
- New Review Highlights Intelligent Agents as Next Step for Digital Pathology
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Channels
Clinical Chemistry
view channel
Childhood Blood Biomarkers May Reveal Early Heart, Kidney, and Metabolic Risks
Cardiovascular, kidney, and metabolic disorders often begin with subtle biological changes that are difficult to recognize in childhood. Identifying these changes early... Read more
International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read moreMolecular Diagnostics
view channel
Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
Early detection of stage I solid cancers remains a significant unmet clinical need. Liquid biopsy approaches that can distinguish tumor-derived signals from background cell-free DNA are therefore drawing... Read more
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read moreHematology
view channel
Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
Immune-mediated thrombosis following heparin therapy can be sudden and severe, creating urgent diagnostic challenges. In heparin-induced thrombocytopenia (HIT), antibodies against platelet factor 4 (PF4)... Read more
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read moreTechnology
view channel
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
H.U. Group Holdings Inc. (Tokyo, Japan) and its wholly owned subsidiary Fujirebio announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized the Lumipulse G NfL Blood and Lumipulse G... Read more







